What AI says about IMMUNOACT

ImmunoACT develops and manufactures CAR T cell therapies, including India's first approved CAR T therapy NexCAR19, which genetically modifies a patient's immune cells to fight cancer. The company partners with Cipla to commercialize Talicabtagene autoleucel in Africa, expanding access to advanced cancer care in South Africa, Algeria, and Morocco.